← All trials
NCT05137184
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 12, 2021
- Primary completion
- Nov 30, 2023
- Completion date
- Nov 30, 2023
- First posted
- Nov 30, 2021
- Last posted
- Nov 30, 2021
- Enrollment
- 270
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of OsloLead sponsor
- University of OsloReponsible party - principal investigator
- University of OsloCollaborator
- Sykehuset Innlandet HFCollaborator
- Norwegian Air Ambulance FoundationCollaborator
- Singapore Eye Research InstituteOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.